Chemoinformaics analysis of 2-Butyne-1,4-diol
| Molecular Weight | 86.09 | nRot | 0 |
| Heavy Atom Molecular Weight | 80.042 | nRig | 1 |
| Exact Molecular Weight | 86.0368 | nRing | 0 |
| Solubility: LogS | 0.867 | nHRing | 0 |
| Solubility: LogP | -1.088 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 12 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 6 | No. of Aromatic Carbocycles | 0 |
| nHetero | 2 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 6 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 4 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 2 | No. of Arom Bond | 0 |
| nHA | 2 | APOL | 12.2848 |
| nHD | 2 | BPOL | 6.01924 |
| QED | 0.37 |
| Synth | 3.053 |
| Natural Product Likeliness | 0.776 |
| NR-PPAR-gamma | 0.003 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0.017 |
| Pgp-sub | 0.001 |
| HIA | 0.032 |
| CACO-2 | -4.335 |
| MDCK | 0.000404569 |
| BBB | 0.993 |
| PPB | 0.362636 |
| VDSS | 0.586 |
| FU | 0.623584 |
| CYP1A2-inh | 0.041 |
| CYP1A2-sub | 0.098 |
| CYP2c19-inh | 0.025 |
| CYP2c19-sub | 0.401 |
| CYP2c9-inh | 0.005 |
| CYP2c9-sub | 0.196 |
| CYP2d6-inh | 0.002 |
| CYP2d6-sub | 0.157 |
| CYP3a4-inh | 0.004 |
| CYP3a4-sub | 0.103 |
| CL | 5.085 |
| T12 | 0.907 |
| hERG | 0.002 |
| Ames | 0.243 |
| ROA | 0.965 |
| SkinSen | 0.872 |
| Carcinogencity | 0.228 |
| EI | 0.996 |
| Respiratory | 0.82 |
| NR-Aromatase | 0.013 |
| Antiviral | No |
| Prediction | 0.984427 |